212 related articles for article (PubMed ID: 34476406)
1. Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.
Degner KR; Wilson NA; Reese SR; Parajuli S; Aziz F; Garg N; Mohamed M; Singh T; Mandelbrot DA; Panzer SE; Redfield RR; Van Hyfte K; Zhong W; Hidalgo LG; Djamali A
Kidney360; 2020 May; 1(5):389-398. PubMed ID: 34476406
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Mediated Rejection Due to Preexisting versus
Aubert O; Loupy A; Hidalgo L; Duong van Huyen JP; Higgins S; Viglietti D; Jouven X; Glotz D; Legendre C; Lefaucheur C; Halloran PF
J Am Soc Nephrol; 2017 Jun; 28(6):1912-1923. PubMed ID: 28255002
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P
PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684
[TBL] [Abstract][Full Text] [Related]
8. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
[TBL] [Abstract][Full Text] [Related]
9. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
[TBL] [Abstract][Full Text] [Related]
10. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
[TBL] [Abstract][Full Text] [Related]
11. Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.
Koslik MA; Friebus-Kardash J; Heinemann FM; Kribben A; Bräsen JH; Eisenberger U
Front Med (Lausanne); 2022; 9():816555. PubMed ID: 35174191
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics and outcomes of late acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience.
Larpparisuth N; Premasathian N; Vareesangthip K; Cheunsuchon B; Parichatikanon P; Vongwiwatana A
Transplant Proc; 2014; 46(2):477-80. PubMed ID: 24655993
[TBL] [Abstract][Full Text] [Related]
13. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.
Zhang H; Zheng C; Li X; Fu Q; Li J; Su Q; Zeng L; Liu Z; Wang J; Huang H; Xu B; Ye M; Liu L; Wang C
Front Immunol; 2020; 11():342. PubMed ID: 32184785
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients.
Pilon C; Bigot J; Grondin C; Thiolat A; Lang P; Cohen JL; Grimbert P; Matignon M
Front Immunol; 2020; 11():34. PubMed ID: 32038663
[TBL] [Abstract][Full Text] [Related]
17. Impact of the immunotherapy induction on allograft outcome and survival in kidney transplant patients with donor-specific antibodies to HLA-DQB1.
Dutra RS; Fabreti-Oliveira RA; Lasmar MF; Araujo SA; Nascimento E
Transpl Immunol; 2021 Jun; 66():101390. PubMed ID: 33838296
[TBL] [Abstract][Full Text] [Related]
18. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
19. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.
Parajuli S; Mandelbrot DA; Muth B; Mohamed M; Garg N; Aziz F; Redfield RR; Zhong W; Astor BC; Djamali A
Transplant Direct; 2017 Dec; 3(12):e227. PubMed ID: 29536028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
